Menu
Search
|

Menu

Close
X

Ocular Therapeutix Inc OCUL.OQ (NASDAQ Stock Exchange Global Market)

5.34 USD
+0.30 (+5.95%)
As of Nov 15
chart
Previous Close 5.04
Open 5.11
Volume 100,290
3m Avg Volume 88,148
Today’s High 5.52
Today’s Low 5.11
52 Week High 8.26
52 Week Low 3.30
Shares Outstanding (mil) 41.10
Market Capitalization (mil) 217.39
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
2
FY16
2
FY15
2
EPS (USD)
FY18
-1.148
FY17
-2.203
FY16
-1.801
FY15
-1.703
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.53
Price to Sales (TTM)
vs sector
110.18
22.95
Price to Book (MRQ)
vs sector
4.71
4.15
Price to Cash Flow (TTM)
vs sector
--
20.94
Total Debt to Equity (MRQ)
vs sector
31.12
15.47
LT Debt to Equity (MRQ)
vs sector
17.74
11.13
Return on Investment (TTM)
vs sector
-100.95
13.00
Return on Equity (TTM)
vs sector
-136.74
14.69

EXECUTIVE LEADERSHIP

Amarpreet Sawhney
Executive Chairman of the Board, Since 2017
Salary: $540,788.00
Bonus: $237,946.00
Antony Mattessich
President, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Donald Notman
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Daniel Bollag
Senior Vice President - Regulatory Affairs, Pharmacovigilance and Quality, Since 2017
Salary: --
Bonus: --
Kevin Hanley
Senior Vice President - Technical Operations, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

15 Crosby Dr
BEDFORD   MA   01730-1401

Phone: +1781.8953235

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

SPONSORED STORIES